The number of women who've told me they were handed an antidepressant, a heart monitor, or a referral to a psychiatrist before anyone mentioned perimenopause is genuinely staggering. It's not that the doctors were careless — it's that hormonal transition simply isn't on the checklist the way it should be. If something in this list sounds familiar, that recognition alone can be worth months of unnecessary investigation.
Learn more about Rose →Estrogen plays a direct role in regulating the autonomic nervous system and cardiac conduction, so as levels fluctuate in perimenopause, many women experience pounding, racing, or irregular heartbeats that feel genuinely alarming. These episodes often prompt ECGs, Holter monitors, and cardiology referrals — most of which come back normal, because the cause is hormonal, not structural. The palpitations tend to cluster around hot flashes or occur at night, which is a useful clue that hormonal fluctuation is driving them.
The explosive, out-of-character anger that many women experience in perimenopause can be severe enough to prompt psychiatric referral, and the episodic nature of it — intense mood swings cycling over days or weeks — can look convincingly like a mood disorder on paper. What's actually happening is that fluctuating estrogen and progesterone directly affect GABA receptors and serotonin pathways, producing genuine neurological instability rather than a personality or mood condition. Women who have no prior psychiatric history and whose rage correlates with cycle changes or other menopause symptoms deserve a hormonal evaluation before a psychiatric label is applied.
Word-finding difficulties, memory lapses, and an inability to concentrate are among the most distressing cognitive symptoms of menopause, and they frequently send women — and their doctors — down the path of cognitive decline screening or adult ADHD assessment. The underlying mechanism is well-documented: estrogen supports hippocampal function, glucose metabolism in the brain, and neurotransmitter signalling, all of which are disrupted during the hormonal transition. Critically, this cognitive dip is largely temporary and tracks closely with the transition itself rather than representing progressive neurodegeneration.
Genitourinary syndrome of menopause (GSM) causes thinning and inflammation of the vaginal and urethral tissues, producing urgency, frequency, burning on urination, and a persistent feeling of bladder irritation — a symptom cluster that is almost indistinguishable from a urinary tract infection. Many women are prescribed repeated courses of antibiotics for cultures that come back negative or borderline, without anyone investigating the underlying tissue atrophy. GSM is both underdiagnosed and highly treatable, which makes this particular misdiagnosis especially frustrating.
Estrogen has significant anti-inflammatory properties, and its decline triggers widespread musculoskeletal inflammation that produces joint pain, morning stiffness, and aching that can closely mimic autoimmune arthritis. Women are frequently referred for rheumatological workups, and while inflammatory markers may be mildly elevated, full autoimmune panels often come back inconclusive. The distribution of the pain — often symmetrical, affecting hands, knees, and hips, worsening around the time of other menopause symptoms — is the clue that hormones are the more likely culprit.
The inability to fall asleep, stay asleep, or achieve restorative sleep is one of the most prevalent and debilitating menopause symptoms, yet it is routinely treated as a standalone sleep disorder or framed as anxiety-driven insomnia without any hormonal investigation. The real architecture of the problem involves night sweats fragmenting sleep, progesterone loss reducing the natural sedative effect that allopregnanolone (a progesterone metabolite) normally provides, and cortisol dysregulation shifting the body's circadian rhythm. Treating the sleep symptom in isolation without addressing hormonal context tends to produce limited and temporary results.
Episodes of dizziness, lightheadedness, and true vertigo are reported by a significant proportion of perimenopausal women, yet they are rarely connected to hormones in initial clinical assessments. Estrogen receptors exist throughout the vestibular system and inner ear, and fluctuating levels can disrupt fluid balance and neural signalling in ways that produce genuine vertigo episodes. Women with no prior ear pathology who develop new-onset dizziness during their mid-forties to early fifties should have hormonal status considered alongside ENT investigation.
Formication — the sensation of insects crawling under or on the skin — is a recognised but rarely discussed menopause symptom that can be frightening enough to prompt neurological investigation for peripheral neuropathy, MS, or even delusional parasitosis. The mechanism is thought to involve estrogen's role in maintaining peripheral nerve sensitivity and skin receptor function; as levels drop, altered sensory signalling produces these unusual tactile sensations. Women who present with this symptom alongside other menopause markers deserve a hormonal conversation before extensive neurological workup.
Low mood, anhedonia, tearfulness, and withdrawal during perimenopause are frequently diagnosed as a depressive episode and treated with antidepressants alone — which may help but does not address the underlying hormonal driver. The perimenopausal brain is genuinely more vulnerable to depression due to estrogen's modulatory effect on serotonin, dopamine, and norepinephrine; this is a distinct neurobiological state that is not simply a life-stage emotional reaction. Research shows that for perimenopausal women, hormone therapy can be as effective as antidepressants for mood symptoms, yet it is rarely offered as part of the first-line conversation.
Bloating, cramping, altered bowel habits, and increased gut sensitivity that emerge or worsen during perimenopause are commonly labelled as irritable bowel syndrome or attributed to newly developed intolerances, sending women toward elimination diets and gastroenterology referrals. Estrogen and progesterone both influence gut motility and the gut microbiome, so hormonal fluctuation directly affects digestive function — progesterone in particular slows gut transit, while estrogen influences intestinal permeability. When GI symptoms track alongside the menstrual cycle or cluster with other perimenopause markers, hormonal context should be part of the clinical picture.
Diffuse hair thinning, increased shedding, and changes in hair texture during perimenopause are regularly investigated as autoimmune alopecia or thyroid dysfunction — and while thyroid function is genuinely worth checking given how often the two conditions coincide, the hormonal contribution is frequently overlooked even when thyroid results are normal. The decline in estrogen and progesterone, combined with a relative increase in androgen activity, shifts hair follicles into a shorter growth phase and accelerates shedding across the scalp. When thyroid panels come back unremarkable and the timeline aligns with other perimenopausal changes, the hormonal explanation deserves equal weight in the clinical conversation.
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.